Management of pembrolizumab-induced steroid refractory mucositis with infliximab: A case report

Figure 3 Direct laryngoscopy. A: January 2019, before infliximab treatment: Massive swelling of posterior supraglottic larynx obliterating normal posterior supraglottic landmarks and diffuse inflamed granular mucosa with weeping character involving nearly all of supraglottic larynx and much of lower pharynx. Supraglottic mass encroaches over posterior supraglottic laryngeal airway. True vocal cords remain clear and mobile; B: May 2019, after infliximab treatment: Resolution of mucosal inflammation but with residual posterior supraglottic submucosal scarring with continued obliteration of posterior supraglottic landmarks and now additional lower supraglottic web. Both true vocal cords continue to look normal and maintain mobility.